179 related articles for article (PubMed ID: 7951238)
1. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B
Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
[TBL] [Abstract][Full Text] [Related]
2. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
3. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype.
Marez D; Sabbagh N; Legrand M; Lo-Guidice JM; Boone P; Broly F
Pharmacogenetics; 1995 Oct; 5(5):305-11. PubMed ID: 8563771
[TBL] [Abstract][Full Text] [Related]
4. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
[TBL] [Abstract][Full Text] [Related]
5. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.
Tyndale R; Aoyama T; Broly F; Matsunaga T; Inaba T; Kalow W; Gelboin HV; Meyer UA; Gonzalez FJ
Pharmacogenetics; 1991 Oct; 1(1):26-32. PubMed ID: 1844820
[TBL] [Abstract][Full Text] [Related]
6. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.
Marez D; Legrand M; Sabbagh N; Lo-Guidice JM; Boone P; Broly F
Hum Genet; 1996 May; 97(5):668-70. PubMed ID: 8655150
[TBL] [Abstract][Full Text] [Related]
7. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
8. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.
Daly AK; Leathart JB; London SJ; Idle JR
Hum Genet; 1995 Mar; 95(3):337-41. PubMed ID: 7868129
[TBL] [Abstract][Full Text] [Related]
9. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.
Evert B; Griese EU; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 1994 Oct; 350(4):434-9. PubMed ID: 7845481
[TBL] [Abstract][Full Text] [Related]
10. Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon.
Evert B; Griese EU; Eichelbaum M
Pharmacogenetics; 1994 Oct; 4(5):271-4. PubMed ID: 7894499
[No Abstract] [Full Text] [Related]
11. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene.
Steen VM; Molven A; Aarskog NK; Gulbrandsen AK
Hum Mol Genet; 1995 Dec; 4(12):2251-7. PubMed ID: 8634695
[TBL] [Abstract][Full Text] [Related]
12. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA
Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
[TBL] [Abstract][Full Text] [Related]
13. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
Douglas AM; Atchison BA; Somogyi AA; Drummer OH
Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
[No Abstract] [Full Text] [Related]
14. Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.
Mura C; Gerard N; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
Br J Clin Pharmacol; 1993 Feb; 35(2):161-5. PubMed ID: 8095148
[TBL] [Abstract][Full Text] [Related]
15. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
Kagimoto M; Heim M; Kagimoto K; Zeugin T; Meyer UA
J Biol Chem; 1990 Oct; 265(28):17209-14. PubMed ID: 2211621
[TBL] [Abstract][Full Text] [Related]
16. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.
Kimura S; Umeno M; Skoda RC; Meyer UA; Gonzalez FJ
Am J Hum Genet; 1989 Dec; 45(6):889-904. PubMed ID: 2574001
[TBL] [Abstract][Full Text] [Related]
17. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
[TBL] [Abstract][Full Text] [Related]
18. An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype.
Panserat S; Mura C; Gérard N; Vincent-Viry M; Galteau MM; Jacoz-Aigrain E; Krishnamoorthy R
Br J Clin Pharmacol; 1995 Oct; 40(4):361-7. PubMed ID: 8554938
[TBL] [Abstract][Full Text] [Related]
19. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
[TBL] [Abstract][Full Text] [Related]
20. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
